Matritech and Bayer in cervical test tie-up
This article was originally published in Clinica
Executive Summary
Bayer will gain the rights to develop new cervical cancer detection systems based on Matritech's patented Nuclear Matrix Protein (NMP) technology under a product development and marketing option agreement just signed with the US based company. In return, Matritech would receive an initial payment plus further milestone and option payments. If Bayer's US Diagnostics Division exercises its marketing option, it will have the exclusive worldwide right to sell automated NMP-based cervical cancer systems utilising raw materials supplied by its new partner.